CIRM

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Retina, Chair, Three Months, Biologics license application, Secretome, Disease, Infection, Incidence, Paratriathlon, Inflammation, Patient, Sale, Limbal stem cell, Research, CIRM, Acquisition, Commercial, Eye, Safety, Retinitis pigmentosa, Food, FDA, BLA, Stargardt disease, Physician, Contingency, Protease, Cryptocurrency

ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • “In 2023, we focused on clinical execution, advancing our Phase 2b CHASE trial of KPI-012 for the treatment of PCED.
  • In December 2023 and March 2024, KALA announced private placement financings with an institutional investor, priced at-the-market under Nasdaq rules.
  • Cash Position: As of December 31, 2023, KALA had cash and cash equivalents of $50.9 million, compared to $56.1 million as of September 30, 2023.
  • Operating Loss: For the quarter ended December 31, 2023, loss from operations was $9.6 million, compared to $10.3 million for the same period in 2022.

KECK GRADUATE INSTITUTE SELECTS DR. MOHAMED ABOUSALEM AS ITS THIRD PRESIDENT

Retrieved on: 
Tuesday, March 12, 2024
Research, University, Organization, Innovation, Growth, Civil engineering, Science, Health, Assistant, Regenerative medicine, Trustee, Education, History, CIRM, SJSU, Engineering, KGI, Knight Foundation, MBA, SAN, Silicon, Claremont Colleges, Alexandria University, Santa Clara University, Sheldon Schuster, Keck Graduate Institute, Marketing, Management

As the Vice President for Research and Innovation at San José State University (SJSU), Dr. Abousalem provided executive leadership to the growth of the university’s research and innovation enterprise.

Key Points: 
  • As the Vice President for Research and Innovation at San José State University (SJSU), Dr. Abousalem provided executive leadership to the growth of the university’s research and innovation enterprise.
  • Dr. Abousalem has held several executive roles for organizations in Silicon Valley and Canada, leading product and corporate development, general management, marketing communications, and human resources of several worldwide business operations.
  • "I am thrilled and privileged to have been chosen to lead KGI at this exciting and transformational time in its history," Dr. Abousalem said.
  • and Ph.D. in Geomatics Engineering from the University of Calgary, Canada, and an MBA from Santa Clara University.

Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers

Retrieved on: 
Tuesday, April 2, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, HCC, Clinical Pediatrics, UCSF, AFP, Regenerative medicine, Patient, Hepatoblastoma, HB, CIRM, Cancer, Doctor of Philosophy, ARTEMIS, MD, Therapy, Hepatocellular carcinoma, Liver, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
  • The ARYA-2 trial is evaluating Eureka’s investigational ARTEMIS® ET140203 T-cell therapy which targets the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex.
  • This therapy is designed to treat pediatric subjects (1 to 21 years) with relapsed or refractory liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), and hepatocellular carcinoma (HCC).
  • For more information on the ARYA-2 trial, Eureka’s T-cell therapy platform, and the potential of this treatment, please visit eurekaconnectme.com .

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Retrieved on: 
Friday, March 15, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Lung cancer, Ovarian cancer, B cell, Metastasis, Patient, City, CIRM, Virus, Cancer, Clinical trial, Supernova, Immune system, Patent, Dove Medical Press

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.

Key Points: 
  • Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.
  • “Calidi continues to make great progress across our development programs while continuing to innovate and expand our industry-leading position in cell-based immunotherapies,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Publicly announced novel systemic enveloped oncolytic virotherapy program, RTNova (CLD-400), targeting advanced solid tumors, including advanced metastatic disease.
  • General and administrative expenses were $16.0 million for the year ended December 31, 2023, compared to $15.9 million for the year ended December 31, 2022, respectively.

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Retrieved on: 
Monday, March 11, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ovarian cancer, Regenerative medicine, Patient, City, CIRM, Woman, Neoplasm, Cancer, Safety, Division, FDA, Dove Medical Press, NSC, Pharmaceutical industry

CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.

Key Points: 
  • CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.
  • This proposed CLD-101 treatment utilizes a neural stem cell line to deliver an oncolytic adenovirus directly to abdominal ovarian tumor sites.
  • In this trial, CLD-101 demonstrated safety and the stimulation of an anti-tumor response, with results published in Lancet Oncology .
  • Aboody has financial interest in and is a paid advisory board member for Calidi Biotherapeutics.

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Monday, February 26, 2024
Neoplasm, Regenerative medicine, CIRM, B-cell lymphoma, Graft-versus-host disease, Investment, TRAC, ADR, CD19, Cytokine release syndrome, Cell, Destiny, HER2, BCMA, Lupus, IPSC, Safety, GAAP, Therapy, Trastuzumab, Pharmacokinetics, Lymphoid leukemia, Patient, NK, Multiple myeloma, SLE, Immunotherapy, Research, CRS, Vaccine

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Total Operating Expenses: For the fourth quarter of 2023, GAAP operating expenses were $49.8 million, including research and development expenses of $31.8 million and general and administrative expenses of $17.9 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of December 31, 2023.
  • ET to review financial and operating results for the quarter and full year ended December 31, 2023.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024
Health, Stem Cells, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Spinal cord, University, CIRM, Roche, Delivery, Interest, Expense, Partnership, Food, Inda, Genentech, Geographic atrophy, Therapy, Webcast, AMD, Patient, Drug discovery, Congress, Survival, G&A, IND, Trial of the century, Research, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Retrieved on: 
Thursday, March 7, 2024
Oncology, Health, Surgery, Stem Cells, Neurology, Biotechnology, Glioblastoma, Bangladesh Technical Education Board, Traffic barrier, Neoplasm, Regenerative medicine, Neurosurgery, Valadez, Multimedia, CIRM, Cerebrospinal fluid, City, Food, Cancer, GBM, Radiation, National Cancer Institute, Heritage, Human, Stroke, Safety, Organization, Patient, Spinal cord, Translational Genomics Research Institute, Brain, Survival, DSM-IV codes, Research, Environment

One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.

Key Points: 
  • One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.
  • Twenty-nine of the 58 patients with recurrent high-grade glioma brain tumors, mostly glioblastoma, achieved stable disease after treatment with CAR T cells for at least two months.
  • There were two partial responses, one complete response and a second complete response after additional CAR T cell therapy cycles were delivered under compassionate use.
  • The study team also included researchers from Translational Genomics Research Institute in Phoenix, which is part of City of Hope.

Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health Technology, Health, Oncology, Neoplasm, Division, Senior, Investigational New Drug, CHLA, Regenerative medicine, Doctor of Philosophy, Multimedia, CIRM, Transplant, FDA, CBDI, TGFB, Sarcoma, Cell, Radiation, Interim, Survival rate, Bone marrow, Hematology, Virus, Tumor microenvironment, USC, Patient, Clinical trial, Survival, Research, Medicine, Vaccine

Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.

Key Points: 
  • Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.
  • (Photo: Business Wire)
    When cancer reoccurs in children and young adults with solid tumors such as sarcomas and neuroblastomas, there are few good treatment options.
  • This is why Children’s Hospital Los Angeles researchers focus on finding novel therapies using the patient’s own immune cells to treat childhood cancers.
  • In 2022, CIRM awarded $8 million to the Keck School of Medicine of USC and Children’s Hospital Los Angeles to establish a CIRM Alpha Clinic.